NCT05879744
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: Strategic business decision Show 4 more changesShow less
- Final enrollment: 3 participants, 3% of the 90 planned
- Eligibility criteria expanded, about 42 words
- Primary completion date changed from estimate of Nov 2026 to Jun 1, 2024
- Secondary endpoints: details revised at 3 of 7 entries
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 6 of 6 sites
- Minor Site details revised at 4 of 6 sitesv5
- Minor Site details revised at 1 of 6 sitesv4
- Minor Study sites: 5 to 6v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary endpoints revised (2)
- Start date changed from estimate of Jun 15, 2023 to May 31, 2023
- Site details revised at 5 of 5 sites
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Safety and tolerability of CLN-978 based on AEs, AESIs, and SAEs
Timeframe: 24 months
Define dose regimen for CLN-978
Timeframe: 24 months
Secondary (7)
Assess preliminary efficacy of CLN-978 by overall response in patients with selective histologies of R/R B-NHL
Assess preliminary efficacy of CLN-978 by complete response in patients with selective histologies of R/R B-NHL
Assess preliminary efficacy of CLN-978 by duration of response in patients with selective histologies of R/R B-NHL
Select PK parameters of CLN-978: AUC
Select PK parameters of CLN-978: Cmax
Show 2 moreShow less
Select PK parameters of CLN-978: Half-life
Immunogenicity of CLN-978 and potential impact on drug exposure
Arms and interventions
Part A Dose EscalationExperimental
Patients with R/R B-NHL treated with CLN-978 in dose escalation cohorts
Part B Dose ExpansionExperimental
Patients with R/R DLBCL, R/R FL and other R/R B-NHL treated with CLN-978 at a dose selected from the Part A Dose Escalation arm.
Drugs: CLN-978
Sites
6 sites in 1 country